Human amylin aggregates into amyloid fibrils, which makes it undruggable. Pramlintide substitutes three prolines — borrowed from rat amylin, which does not aggregate — producing a soluble analog with retained activity. It slows gastric emptying, suppresses inappropriate postprandial glucagon, and promotes satiety via the area postrema. It is the approved proof-of-concept for the mechanism cagrilintide is now pursuing.
Approved in 2005 on trials in type 1 and type 2 diabetes as mealtime adjunct therapy to insulin. Commercially marginal, but the pharmacology is established.
FDA-approved as adjunct mealtime therapy with insulin in type 1 and type 2 diabetes. Prescription-only.
Boxed warning for severe insulin-induced hypoglycaemia, typically within three hours of dosing. Requires concurrent insulin dose reduction and close glucose monitoring — this is genuinely a drug that kills people who use it casually. Nausea is common.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.